KCNN4 and multiple sclerosis: Based on this expression pattern, Kv1.3 blockers are currently in Phase-1 clinical trials for multiple sclerosis [13] and psoriasis, while KCa3.1 blockers are being investigated for conditions such as asthma, restenosis disease, kidney fibrosis and atherosclerosis, which in addition to involving T cells and macrophages also have a vascular smooth muscle cell and fibroblast proliferative component [14].